Evidence map›Paper›PMID 24519091›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2014

Cellular and molecular studies of the effects of a selective COX-2 inhibitor celecoxib in the cardiac cell line H9c2 and their correlation with death mechanisms.

K K Sakane, C J Monteiro, W Silva, A R Silva, P M Santos, K F Lima, K C M Moraes

Open access · goldAbstract read
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species.Oxidative medicine and cellular longevity · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

K K SakaneUniversidade do Vale do Paraíba, Instituto de Pesquisa e Desenvolvimento, São José dos CamposSP, Brasil, Instituto de Pesquisa e Desenvolvimento, Universidade do Vale do Paraíba, São José dos Campos, SP, Brasil.
C J MonteiroUniversidade Federal de Ouro Preto, Núcleo de Pesquisa em Ciências Biológicas, Ouro PretoMG, Brasil, Núcleo de Pesquisa em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.
W SilvaUniversidade Federal de Ouro Preto, Núcleo de Pesquisa em Ciências Biológicas, Ouro PretoMG, Brasil, Núcleo de Pesquisa em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.
A R SilvaUniversidade Federal de Ouro Preto, Núcleo de Pesquisa em Ciências Biológicas, Ouro PretoMG, Brasil, Núcleo de Pesquisa em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.
P M SantosUniversidade do Vale do Paraíba, Instituto de Pesquisa e Desenvolvimento, São José dos CamposSP, Brasil, Instituto de Pesquisa e Desenvolvimento, Universidade do Vale do Paraíba, São José dos Campos, SP, Brasil.
K F LimaUniversidade Federal de Ouro Preto, Núcleo de Pesquisa em Ciências Biológicas, Ouro PretoMG, Brasil, Núcleo de Pesquisa em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.
K C M MoraesUniversidade Estadual Paulista "Júlio de Mesquita Filho", Departamento de Biologia, Instituto de Biociências, Rio ClaroSP, Brasil, Instituto de Biociências, Departamento de Biologia, Universidade Estadual Paulista ''Júlio de Mesquita Filho'', Rio Claro, SP, Brasil.
Universidade Federal de Ouro Preto · BRUniversidade do Vale do Paraíba · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease is one of the leading causes of death worldwide, and evidence indicates a correlation between the inflammatory process and cardiac dysfunction. Selective inhibitors of cyclooxygenase-2 (COX-2) enzyme are not recommended for long-term use because of potentially severe side effects to the heart. Considering this and the frequent prescribing of commercial celecoxib, the present study analyzed cellular and molecular effects of 1 and 10 µM celecoxib in a cell culture model. After a 24-h incubation, celecoxib reduced cell viability in a dose-dependent manner as also demonstrated in MTT assays. Furthermore, reverse transcription-polymerase chain reaction analysis showed that the drug modulated the expression level of genes related to death pathways, and Western blot analyses demonstrated a modulatory effect of the drug on COX-2 protein levels in cardiac cells. In addition, the results demonstrated a downregulation of prostaglandin E2 production by the cardiac cells incubated with celecoxib, in a dose-specific manner. These results are consistent with the decrease in cell viability and the presence of necrotic processes shown by Fourier transform infrared analysis, suggesting a direct correlation of prostanoids in cellular homeostasis and survival.

Indexed as

AnimalsBlotting, WesternCelecoxibCell LineCell ProliferationCell SurvivalCyclooxygenase 2 InhibitorsDose-Response Relationship, DrugGene Expression RegulationMyoblasts, CardiacPyrazolesRatsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSpectroscopy, Near-InfraredSulfonamidesCelecoxibCyclooxygenase 2 InhibitorsPyrazolesRNA, MessengerSulfonamides

Identifiers

PMID24519091
PMCPMC3932973
OpenAlexW2105686300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.